TAN-118 Phase IIa induction therapy in moderate to severe active ulcerative colitis

Phase 2, randomised, double-blind trial in autoimmune colitis comparing TAN-118 tablets with Placebo (2 arms). Primary endpoints: Incidence, severity, outcome and drug-relatedness of adverse events and serious adverse events during treatment, Incidence of adverse events leading to study drug interruption or permanent discontinuation and 2 more. Planned start May 2026; status: not yet recruiting.